Dissecting PARP inhibitor resistance with functional genomics

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Poly-(ADP-ribose) polymerase inhibitors (PARPi) represent a targeted therapy for inherited cancers, particularly those with BRCA1/BRCA2 mutations.
• Olaparib was the first PARPi approved, and subsequent drugs are used for ovarian, gynecological, and breast cancers with BRCA mutations.
• Tumor resistance to PARPi is a significant clinical challenge, necessitating a deeper molecular understanding.

Purpose of the Study:

• To review functional genomic strategies used to investigate the molecular basis of PARPi sensitivity and resistance.
• To highlight the evolution and impact of genetic perturbation techniques in dissecting drug response mechanisms.
• To emphasize the role of CRISPR-Cas9 in advancing preclinical models for PARPi research.

Main Methods:

• Review of low-throughput, hypothesis-testing experiments using classical gene targeting, siRNA, shRNA, and transposon mutagenesis.
• Analysis of large-scale, hypothesis-generating genetic screens.
• Focus on the application and advancements of CRISPR-Cas9-based mutagenesis in cancer models.

Main Results:

• Functional genomic strategies have been instrumental in identifying molecular mechanisms underlying PARPi sensitivity and resistance.
• CRISPR-Cas9 technology has significantly enhanced the precision and scope of preclinical models for studying drug response.
• These approaches provide critical insights into how tumor cells respond to PARPi at a molecular level.

Conclusions:

• Understanding PARPi resistance through functional genomics is essential for optimizing clinical drug use.
• CRISPR-Cas9 and other genetic screening methods offer powerful tools for dissecting complex drug resistance pathways.
• Continued research using these strategies holds promise for developing more effective cancer therapies.